OnCo

Wilms tumour (nephroblastoma): lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersRisk group
Early / localised11
Locally advanced1·
Second line1·

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersStage I-II favourable histologyNephrectomy then vincristine + actinomycin D for 18 weeks (EE-4A), or SIOP pre-op VA ×4 weeks then stage-adapted post-op therapy.39
Risk groupVery low risk (stage I FH, <2 years, <550 g)Nephrectomy alone with close surveillance (AREN0532).63

Locally advanced

SubgroupSettingApproachProducts and trialsEvidence
All comersStage III-IV favourable histologyVincristine, actinomycin D, doxorubicin (DD-4A) for 24 weeks; flank/abdominal radiotherapy for stage III; whole-lung radiotherapy for lung metastases not in rapid complete response (AREN0533).91

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersDiffuse anaplastic or relapsedIntensive UH-1/UH-2 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide) with radiotherapy; relapse: ICE-type regimens, surgery, RT, high-dose therapy or trials.81

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.